Key result
Visceral adiposity index was a significant determinant of metabolic syndrome in both obese (OR 1.17) and non-obese (OR 1.20) women with polycystic ovary syndrome.
Why the study?
Polycystic ovary syndrome is an escalating endocrine and reproductive burden, prompting evaluation of the potential association of metabolic syndrome in obese and non-obese PCOS women.
Does the visceral adiposity index predict the presence of metabolic syndrome in obese and non-obese women with polycystic ovary syndrome?
Cross-Sectional (n=250)
No
Does the visceral adiposity index predict the presence of metabolic syndrome in obese and non-obese women with polycystic ovary syndrome?
Odds Ratio: 1.17 (95% CI 1.04–1.32)
p-value: p=<0.01
The visceral adiposity index is a significant and inexpensive clinical tool for the early detection of metabolic syndrome in both obese and non-obese women with polycystic ovary syndrome.
VAI may aid MS screening in PCOS women; leaves open need for prospective validation before clinical adoption.
Background Polycystic ovary syndrome is an escalating endocrinal and reproductive disorder among women of reproductive age and is considered the foremost health burden. Therefore, the present study is an attempt to estimate the potential association of metabolic syndrome in obese and non-obese PCOS women. A total of 250 PCOS women ranging in age from 18 to 45 years and living in the Chandigarh Capital Region were selected from the OPD, PGIMER, Chandigarh, (North India). Rotterdam Criteria (2003) was employed to diagnose polycystic ovary syndrome among women. Results The prevalence of metabolic syndrome (MS) as assessed by the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) was found to be 30% (4% in non-obese and 26% in obese) in PCOS women. Waist circumference > 88 cm is the most prevalent feature in PCOS women (67.2%) followed by HDL < 50 mg/dL (56.8%). The multivariate logistic regression analysis exhibited that visceral adiposity index (VAI) was a significant determinant of metabolic syndrome in obese (OR = 1.17, p < 0.01) and non-obese (OR = 1.2, p < 0.01) PCOS women. Results of ROC analysis further established visceral adiposity index as a potential determinant in metabolic syndrome in both the groups of PCOS women. In obese PCOS women, the W/H ratio also depicted accuracy in predicting metabolic syndrome risk. Conclusions Visceral adiposity index is a significant tool to assess the metabolic syndrome in both groups, i.e., obese and non-obese. However, the waist/hip ratio can be considered as a predictive tool in obese women only. Thus, it could be used as a significant and inexpensive tool in clinical practices for early detection of metabolic syndrome in PCOS women.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2024) conducted a cross-sectional in Polycystic ovary syndrome (PCOS) (n=250). Visceral adiposity index (VAI) was evaluated on Association of visceral adiposity index with metabolic syndrome in obese PCOS women (OR 1.17, 95% CI 1.04-1.32, p=<0.01). Visceral adiposity index was a significant determinant of metabolic syndrome in both obese (OR 1.17) and non-obese (OR 1.20) women with polycystic ovary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: